Background
Renal cell carcinoma (RCC) is responsible for between 80% and 85% of all primary renal neoplasms. In Canada, approximately 6600 new kidney cancer diagnoses were made in 2017 and 1900 patients died from their disease. 1 The increased utilization of diagnostic imaging in general has resulted in more small renal masses being detected, 2 allowing for early intervention.
Patients who undergo pN may be at a decreased risk of cardiovascular disease, anemia, malnutrition, and neuropathy compared to patients who undergo rN. 5 These findings have led to American 6 and European 7 guidelines recommending pN as the standard of care for small renal tumors where technically feasible. In our jurisdiction (Alberta, Canada), pN was initially recommended as the standard treatment for T1a RCC in 2007. Although some controversy remains regarding the optimal surgical approach for small RCC masses, 8 pN has become the primary treatment approach in most jurisdictions. 6, 7 The goal of this study was to evaluate uptake of pN over time and to investigate current pN/rN practice patterns and outcomes in T1a disease.
Methods
We identified 1679 patients diagnosed between 2002 and 2014 that received a pN or rN for T1a RCC through the Alberta Cancer Registry (ACR). Patient/treatment data were collected from the Discharge Abstract Database (DAD), the National Ambulatory Care Reporting System Database (NACRS), ACR, and through manual chart review. Patients were excluded (n=230) for inaccessible or incomplete medical records, multiple tumors, actual tumor size >4 cm after chart review, if they never underwent pN/rN, or because they were on dialysis prior to nephrectomy. This led to a final cohort of N=1449.
Patients were stratified into pre-/post-guideline eras (2002-2007 and 2008-2014 , respectively) based on the Patient and treatment characteristics were compared using monovariate (Chi-square, t-test, or Mann-Whitney, where appropriate), or multivariate analyses (logistical regression). Survival was compared using Kaplan-Meier estimates, Logrank, and Cox Regression. Statistics were performed using SigmaPlot V13.0 (Systat Software Inc.; Chicago, Illinois) or SPSS V19.0 (IBM; Armonk, New York).
This study did not meet the requirement for ethics board review. The study was determined to be low risk as assessed by the ARECCI ethical review system.
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Results
The entire cohort had a mean follow-up of 54 months. Median age was 59 years (range: 21-87 years) with 39.8% females, and a median GFR of 75.9 mL/min/ 1.73m 2 ( Table 1 ).
In total, n=879 patients received pN and n=570 patients received rN. In general, pN utilization increased over time ( Figure 1A Overall, patients who received pN had similar sex compared to rN patients (38.5% vs 41.8% female, respectively, p=0.202); however, pN patients were significantly younger (median 59 vs 60 years, respectively, p=0.033) and had significantly higher baseline GFR (median 78. 4 Table 2) .
Patients who received nephrectomies in the pre-guideline era (2002) (2003) (2004) (2005) (2006) were significantly less likely to have received pN compared to patients receiving nephrectomies in the postguideline era (pre: 37.3%, post: 64.4%, p=0.001). In the preguideline era pN patients were significantly younger than rN patients (median 53 years vs 60 years; p=0.015) and had higher baseline GFR (median 68 mL/min/1.73m 2 vs 59 mL/min/ 1.73m 2 ). Patient age (p=0.896) and sex (p=0.888) were similar between guideline eras; however, baseline GFR was Table 3 ). In the modern era (2011-2014), the odds of receiving a pN were not significantly affected by GFR, Age, or Sex, with the exception of patients with kidney failure (GFR <15), who remained significantly less likely to receive a pN (OR: <0.001, p<0.001).
Discussion
The management of small renal masses has rapidly evolved. Relative to rN, pN is often a more technically challenging procedure; however, the benefits from preserving renal function have led to wide-spread adoption into clinical practice. The utilization of pN as a proportion of total nephrectomies for T1a RCC generally increased over time from 2002 to 2014 ( Figure 1) significant increases in pN use when comparing year-overyear use. Major year-over-year increases in pN use become apparent post-2009, perhaps representing a delay in surgeon uptake 13 or correlating with the reporting of oncological outcomes from the EORTC intergroup phase III trial. 3 Regardless, patients treated in the pre-guideline era, when compared to the post-guideline era, were significantly (OR: 2.709, p<0.001) less likely to receive a pN. In our cohort, pN patients had significantly improved overall survival (Figure 1) , which is likely associated with patient selection as phase III randomized data have shown equivalent outcomes in clinically and pathologically eligible patients, 3 however, pN's superiority did persist when controlled for baseline GFR, age, sex, and guideline era ( Table 2) . As expected, low baseline GFR (15-29 mL/min/1.73m 2 )
was associated with decreased survival. Patients with kidney failure at presentation (GFR <15 mL/min/ 1.73m 2 ) were not at a significantly increased risk of death, likely due to limited statistical power (n=18). Also expected, older age was associated with increased risk of death from any cause and like others, 14 we found that women had significantly reduced risk of death when compared to males. Early studies evaluating pN recommended that the procedure should be reserved for highly selected patients. 15 Over time these recommendations shifted to include all patients who are surgically eligible if the procedure is technically feasible. This transition was apparent in our cohort. In our overall cohort, the adjusted odds of receiving a pN was significantly associated with baseline GFR, with a clear trend towards decreasing pN use with decreased baseline GFR (Table 3) . Age or gender did not appear to affect the odds of receiving a pN in the entire cohort; however, patients aged ≥80 years did trend towards higher rN use (p=0.131).
To evaluate more recent practice patterns we subdivided our cohort into the "modern era" which consisted of all years where pN represented at least 70% of nephrectomies performed in T1a patients (2011) (2012) (2013) (2014) . In this subgroup, no patients with baseline kidney failure (GFR <15 mL/min/1.73m 2 ) received a pN, but otherwise, GFR, age, or sex had no effect on the relative odds of receiving a pN (all p>0.050). This suggests that local guideline recommendations (that all surgically eligible patients should receiving a pN where technically feasible) were adopted within 4 years. As pN use has now been adopted in most jurisdictions, it is important to analyze how that adoption took place as the focus now shifts to utilizing pN for larger renal masses. 16 Despite consensus on evidence-based guidelines in our jurisdiction, a clear lag in uptake was apparent before fairly rapid adoption of recommendations. This major limitations for this study include the inability to adjust for all clinically relevant patient characteristics and decisions that influence the use of pN vs rN. Also, we did not examine the effects of the surgical approach used (open vs laparoscopic vs robot-assisted laparoscopic). Additionally, ablation techniques that may have been used to treat small renal cell carcinomas were not analyzed. However, we do report on a relatively large real-world population of patients with sufficient time to allow for analysis of temporal trends.
